A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
Clinical trial NCT07213830 · RECRUITING
Trial details
- NCT number
- NCT07213830
- Sponsor
- Ipsen
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-02-06
- Primary completion
- 2032-07-14
- Enrollment
- 102
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.